Pureca Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 12.03%
- Profit Growth 352.76%
- Ebitda -4508.14%
- Net Worth 27.17%
- Total Assets 67.15%
About Pureca Laboratories
Pureca Laboratories Private Limited (PLPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 22 May 2012 and has a history of 12 years and nine months. Its registered office is in Delhi, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Arpit Vohra and Vaibhav Vohra serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100DL2012PTC236285
- Company No.
236285
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 May 2012
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Pureca Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arpit Vohra  | Director | 22-May-2012 | Current |
| Vaibhav Vohra | Director | 22-May-2012 | Current |
Financial Performance of Pureca Laboratories.
Pureca Laboratories Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 12.03% increase. The company also saw a substantial improvement in profitability, with a 352.76% increase in profit. The company's net worth Soared by an impressive increase of 27.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pureca Laboratories?
In 2018, Pureca Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Oplos Medicare Pharmaceuticals Private LimitedArpit Vohra and Vaibhav Vohra are mutual person
Dinkum Biological Private LimitedArpit Vohra is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pureca Laboratories?
Pureca Laboratories has a workforce of 4 employees as of Mar 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pureca Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pureca Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
